AIM ImmunoTech appoints Robert Dickey IV as CFO; Lintal transitions to consultant

AIM ImmunoTech Inc.

Robert Dickey IV becomes CFO effective April 4, 2022, replacing Ellen Lintal who moves to consultant role.
Dickey compensated $375/hour under a one-year consulting agreement with his firm Foresite Advisors.
Dickey brings 25+ years of life science CFO and investment banking experience, including 18 years at Lehman Brothers.
He previously served as senior vice president of AIM from 2008 to 2013.
Press release issued March 3, 2022; contract terminable on 60-day notice (non-cause) or 30-day (cause).

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Ellen Lintal

Chief Financial Officer

AIM · AIM ImmunoTech Inc.

Effective: 2022-04-04
Successor: Robert Dickey IV
Filed: March 3, 2022, 6:59 PM ET

On March 1, 2022, the Company entered into a consulting agreement with Ellen Lintal, who will step down as the Company’s Chief Financial Officer on April 4, 2022.

Appointed

Robert Dickey IV

Chief Financial Officer

AIM · AIM ImmunoTech Inc.

Effective: 2022-04-04
Filed: March 3, 2022, 6:59 PM ET

On March 1, 2022, after review and approval by the Board of Directors, the Company entered into a consulting agreement with Foresite Advisors, LLC, a company wholly-owned by Robert Dickey IV, pursuant to which Mr. Dickey will serve as the Company’s new Chief Financial Officer effective April 4, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ellen Lintal departed as Chief Financial Officer at AIM ImmunoTech Inc..

Action: stepped down
Role: Chief Financial Officer

Exact text from the filing

On March 1, 2022, the Company entered into a consulting agreement with Ellen Lintal, who will step down as the Company’s Chief Financial Officer on April 4, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Dickey IV was appointed as Chief Financial Officer at AIM ImmunoTech Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On March 1, 2022, after review and approval by the Board of Directors, the Company entered into a consulting agreement with Foresite Advisors, LLC, a company wholly-owned by Robert Dickey IV, pursuant to which Mr. Dickey will serve as the Company’s new Chief Financial Officer effective April 4, 2022.

View on SEC.gov

AIM ImmunoTech Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-005894

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.